Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

[Changes in selected physiological indicators and thermal stress assessment under the influence of baths in a dry and wet sauna in young healthy women].

Pilch W, Piotrowska A, Czerwińska-Ledwig O, Zuziak R, Maciejczyk M, Tota Ł, Bawelski M, Pałka T.

Med Pr. 2019 Dec 3;70(6):701-710. doi: 10.13075/mp.5893.00883. Epub 2019 Oct 10. Polish.

2.

The Impact of Vibration Therapy Interventions on Skin Condition and Skin Temperature Changes in Young Women with Lipodystrophy: A Pilot Study.

Pilch W, Czerwińska-Ledwig O, Chitryniewicz-Rostek J, Nastałek M, Krężałek P, Jędrychowska D, Totko-Borkusewicz N, Uher I, Kaško D, Tota Ł, Tyka A, Tyka A, Piotrowska A.

Evid Based Complement Alternat Med. 2019 May 29;2019:8436325. doi: 10.1155/2019/8436325. eCollection 2019.

3.

Impact of oscillatory-cycloid vibration interventions on body composition, waist and hip circumference, and blood lipid profile in women aged over 65 years with hypercholesterolaemia.

Piotrowska AM, Bigosińska M, Potok H, Cisoń-Apanasewicz U, Czerwińska-Ledwig O, Tota ŁM, Zuziak R, Pałka T, Pilch W.

Prz Menopauzalny. 2018 Dec;17(4):161-167. doi: 10.5114/pm.2018.81739. Epub 2018 Dec 31.

4.

Muscle and intestinal damage in triathletes.

Tota Ł, Piotrowska A, Pałka T, Morawska M, Mikuľáková W, Mucha D, Żmuda-Pałka M, Pilch W.

PLoS One. 2019 Jan 18;14(1):e0210651. doi: 10.1371/journal.pone.0210651. eCollection 2019.

5.

Effects of Nordic Walking on Oxidant and Antioxidant Status: Levels of Calcidiol and Proinflammatory Cytokines in Middle-Aged Women.

Pilch W, Tota Ł, Piotrowska A, Śliwicka E, Czerwińska-Ledwig O, Zuziak R, Pilaczyńska-Szcześniak Ł.

Oxid Med Cell Longev. 2018 Mar 20;2018:6468234. doi: 10.1155/2018/6468234. eCollection 2018.

6.

The Effect of a 12-Week Health Training Program on Selected Anthropometric and Biochemical Variables in Middle-Aged Women.

Pilch W, Tota Ł, Sadowska-Krępa E, Piotrowska A, Kępińska M, Pałka T, Maszczyk A.

Biomed Res Int. 2017;2017:9569513. doi: 10.1155/2017/9569513. Epub 2017 Oct 9.

7.

[Biological significance of chromium III for the human organism].

Piotrowska A, Pilch W, Tota Ł, Nowak G.

Med Pr. 2018 Mar 9;69(2):211-223. doi: 10.13075/mp.5893.00625. Epub 2017 Oct 12. Review. Polish.

8.

The influence of a 12-week program of physical activity on changes in body composition and lipid and carbohydrate status in postmenopausal women.

Pilch WB, Mucha DM, Pałka TA, Suder AE, Piotrowska AM, Tyka AK, Tota ŁM, Ambroży T.

Prz Menopauzalny. 2015 Dec;14(4):231-7. doi: 10.5114/pm.2015.56311. Epub 2015 Dec 8.

9.

Changes in Endurance Performance in Young Athletes During Two Training Seasons.

Tota Ł, Maciejczyk M, Pokora I, Cempla J, Pilch W, Pałka T.

J Hum Kinet. 2015 Dec 30;49:149-58. doi: 10.1515/hukin-2015-0117. eCollection 2015 Dec 22.

10.

A novel series of indazole-/indole-based glucagon receptor antagonists.

Lin S, Zhang F, Jiang G, Qureshi SA, Yang X, Chicchi GG, Tota L, Bansal A, Brady E, Trujillo M, Salituro G, Miller C, Tata JR, Zhang BB, Parmee ER.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4143-7. doi: 10.1016/j.bmcl.2015.08.015. Epub 2015 Aug 8.

PMID:
26303893
11.

The effect of sauna bathing on lipid profile in young, physically active, male subjects.

Gryka D, Pilch W, Szarek M, Szygula Z, Tota Ł.

Int J Occup Med Environ Health. 2014 Aug;27(4):608-18. doi: 10.2478/s13382-014-0281-9. Epub 2014 Jul 7.

12.

Comparison of physiological reactions and physiological strain in healthy men under heat stress in dry and steam heat saunas.

Pilch W, Szygula Z, Palka T, Pilch P, Cison T, Wiecha S, Tota L.

Biol Sport. 2014 Jun;31(2):145-9. doi: 10.5604/20831862.1099045. Epub 2014 Apr 5.

13.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA, Tong X, Xu SS, Shang J, Vincent SH, Tota LM, Wright MJ, Yang X, Zhang BB, Tata JR, Parmee ER.

J Med Chem. 2012 Jul 12;55(13):6137-48. doi: 10.1021/jm300579z. Epub 2012 Jun 28.

PMID:
22708876
14.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

Sinz C, Bittner A, Brady E, Candelore M, Dallas-Yang Q, Ding V, Jiang G, Lin Z, Qureshi S, Salituro G, Saperstein R, Shang J, Szalkowski D, Tota L, Vincent S, Wright M, Xu S, Yang X, Zhang B, Tata J, Kim R, Parmee ER.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7124-30. doi: 10.1016/j.bmcl.2011.09.105. Epub 2011 Oct 5.

PMID:
22030028
15.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

Sinz C, Chang J, Lins AR, Brady E, Candelore M, Dallas-Yang Q, Ding V, Jiang G, Lin Z, Mock S, Qureshi S, Salituro G, Saperstein R, Shang J, Szalkowski D, Tota L, Vincent S, Wright M, Xu S, Yang X, Zhang B, Tata J, Kim R, Parmee E.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7131-6. doi: 10.1016/j.bmcl.2011.09.085. Epub 2011 Sep 29.

PMID:
22001094
16.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

Shen DM, Brady EJ, Candelore MR, Dallas-Yang Q, Ding VD, Feeney WP, Jiang G, McCann ME, Mock S, Qureshi SA, Saperstein R, Shen X, Tong X, Tota LM, Wright MJ, Yang X, Zheng S, Chapman KT, Zhang BB, Tata JR, Parmee ER.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):76-81. doi: 10.1016/j.bmcl.2010.11.074. Epub 2010 Nov 21.

PMID:
21147532
17.

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R.

Diabetes. 2009 Oct;58(10):2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14.

18.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

Kim RM, Chang J, Lins AR, Brady E, Candelore MR, Dallas-Yang Q, Ding V, Dragovic J, Iliff S, Jiang G, Mock S, Qureshi S, Saperstein R, Szalkowski D, Tamvakopoulos C, Tota L, Wright M, Yang X, Tata JR, Chapman K, Zhang BB, Parmee ER.

Bioorg Med Chem Lett. 2008 Jul 1;18(13):3701-5. doi: 10.1016/j.bmcl.2008.05.072. Epub 2008 May 22.

PMID:
18539028
19.

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

Liang R, Abrardo L, Brady EJ, Candelore MR, Ding V, Saperstein R, Tota LM, Wright M, Mock S, Tamvakopolous C, Tong S, Zheng S, Zhang BB, Tata JR, Parmee ER.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):587-92. Epub 2006 Nov 10.

PMID:
17126016
20.

Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.

Cohen SM, Duffy JL, Miller C, Kirk BA, Candelore MR, Ding VD, Kaczorowski G, Tota LM, Werrmann JG, Wright M, Parmee ER, Tata JR, Zhang BB.

Bioorg Med Chem. 2006 Mar 1;14(5):1506-17. Epub 2005 Oct 25.

PMID:
16256355
21.

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

Shen DM, Zhang F, Brady EJ, Candelore MR, Dallas-Yang Q, Ding VD, Dragovic J, Feeney WP, Jiang G, McCann PE, Mock S, Qureshi SA, Saperstein R, Shen X, Tamvakopoulos C, Tong X, Tota LM, Wright MJ, Yang X, Zheng S, Chapman KT, Zhang BB, Tata JR, Parmee ER.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4564-9.

PMID:
16102966
22.

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

Duffy JL, Kirk BA, Konteatis Z, Campbell EL, Liang R, Brady EJ, Candelore MR, Ding VD, Jiang G, Liu F, Qureshi SA, Saperstein R, Szalkowski D, Tong S, Tota LM, Xie D, Yang X, Zafian P, Zheng S, Chapman KT, Zhang BB, Tata JR.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1401-5.

PMID:
15713396
23.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM, Jiang G, Brady E, Saperstein R, Duffy JL, Tata JR, Chapman KT, Moller DE, Zhang BB.

Diabetes. 2004 Dec;53(12):3267-73.

24.

Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor.

Candelore MR, Wright MJ, Tota LM, Milligan J, Shei GJ, Bergstrom JD, Mandala SM.

Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6.

PMID:
12270137
25.

Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.

Brockunier LL, Candelore MR, Cascieri MA, Liu Y, Tota L, Wyvratt MJ, Fisher MH, Weber AE, Parmee ER.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):379-82.

PMID:
11212115
26.

Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.

Parmee ER, Brockunier LL, He J, Singh SB, Candelore MR, Cascieri MA, Deng L, Liu Y, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2283-6.

PMID:
11055339
27.

Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.

Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

J Med Chem. 2000 Oct 19;43(21):3832-6.

PMID:
11052788
28.

L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey.

Forrest MJ, Hom G, Bach T, Candelore MR, Cascieri MA, Strader C, Tota L, Fisher MH, Szumiloski J, Ok HO, Weber AE, Wyvratt M, Vicario P, Marko O, Deng L, Cioffe C, Hegarty-Friscino B, MacIntyre E.

Eur J Pharmacol. 2000 Oct 27;407(1-2):175-81.

PMID:
11050305
29.

Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.

Brockunier LL, Parmee ER, Ok HO, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2111-4.

PMID:
10999482
30.

Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.

Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):1971-3.

PMID:
10987429
31.

Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.

Ok HO, Reigle LB, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang P, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1531-4.

PMID:
10915043
32.

Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.

Feng DD, Biftu T, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1427-9.

PMID:
10888324
33.

Potent and selective human beta(3)-adrenergic receptor antagonists.

Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE.

J Pharmacol Exp Ther. 1999 Aug;290(2):649-55.

PMID:
10411574
34.

Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.

Mathvink RJ, Barritta AM, Candelore MR, Cascieri MA, Deng L, Tota L, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1869-74.

PMID:
10406657
35.

L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.

Shih TL, Candelore MR, Cascieri MA, Chiu SH, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 May 3;9(9):1251-4.

PMID:
10340609
36.

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.

Naylor EM, Parmee ER, Colandrea VJ, Perkins L, Brockunier L, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):755-8.

PMID:
10201842
37.

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.

Parmee ER, Naylor EM, Perkins L, Colandrea VJ, Ok HO, Candelore MR, Cascieri MA, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):749-54.

PMID:
10201841
38.

3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.

Naylor EM, Colandrea VJ, Candelore MR, Cascieri MA, Colwell LF Jr, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1998 Nov 3;8(21):3087-92.

PMID:
9873681
39.

3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.

Weber AE, Ok HO, Alvaro RF, Candelore MR, Cascieri MA, Chiu SH, Deng L, Forrest MJ, Hom GJ, Hutchins JE, Kao J, MacIntyre DE, Mathvink RJ, McLoughlin D, Miller RR, Newbold RC, Olah TV, Parmee ER, Perkins L, Stearns RA, Strader CD, Szumiloski J, Tang YS, Tota L, Fisher MH, et al.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2111-6.

PMID:
9873496
40.

Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.

Parmee ER, Ok HO, Candelore MR, Tota L, Deng L, Strader CD, Wyvratt MJ, Fisher MH, Weber AE.

Bioorg Med Chem Lett. 1998 May 5;8(9):1107-12.

PMID:
9871717
41.

Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.

Weber AE, Mathvink RJ, Perkins L, Hutchins JE, Candelore MR, Tota L, Strader CD, Wyvratt MJ, Fisher MH.

Bioorg Med Chem Lett. 1998 May 5;8(9):1101-6.

PMID:
9871716
42.

Desensitization of beta3-adrenergic receptor-stimulated adenylyl cyclase activity and lipolysis in rats.

Vicario PP, Candelore MR, Schaeffer MT, Kelly L, Thompson GM, Brady EJ, Saperstein R, MacIntyre DE, Tota LM, Cascieri MA.

Life Sci. 1998;62(7):627-38.

PMID:
9472722
43.

Endocardial endothelium in the avascular heart of the frog: morphology and role of nitric oxide.

Sys SU, Pellegrino D, Mazza R, Gattuso A, Andries LJ, Tota L.

J Exp Biol. 1997 Dec;200(Pt 24):3109-18.

44.

Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant.

Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD.

Endocrinology. 1996 Jun;137(6):2638-41.

PMID:
8641219
45.

[Irreducible heart failure due to an anomaly of coronary topography].

Avram R, Bejan L, Stanciu L, Georgescu L, Capetean G, Toţa L.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1985 May-Jun;37(3):237-42. Romanian. No abstract available.

PMID:
2865786

Supplemental Content

Support Center